

Financial Results Briefing for the Third Quarter of Fiscal Year Ending February 2023

January 12, 2023

Welcia Holdings Co., Ltd.

Stock Code 3141, Tokyo Stock Exchange Prime Market

Table of Contents



2

1. Outline of Financial Results		
 Overview of FY2023 3Q 	• • • • • • •	4
 Results for FY2023 3Q (achievement rates) 	• • • • • • •	5
 Results for FY2023 3Q (cumulative YoY change) 	• • • • • • •	6
 Results for FY2023 3Q (quarterly YoY change) 	• • • • • • •	7
 Breakdown of financial results by company for FY2023 3Q 	• • • • • • •	9
 Monthly sales growth rate (in Japan) 	• • • • • • •	11
 Composition ratio of sales by category 	•••••	12
 Gross profit margin by category 	•••••	14
 SG&A expenses composition ratio 	• • • • • • •	16
 Results in the dispensing sector (in Japan) 	• • • • • • •	18
 Promotion of drug stores with dispensing pharmacy 	• • • • • • •	19
 Number of employees 	• • • • • • •	20
 Store openings and closures 	•••••	21
 Efforts for FY2023 3Q 	• • • • • • •	22
 Counseling using digital tools 	•••••	23
 [Reference] Overview of Fukuyakuhin Co., Ltd. 	•••••	24
2. Earnings Forecast for FY2023		
 Indicator assumptions and priority measures for FY2023 forecasts 	• • • • • • •	26
 Efforts for FY2023 	• • • • • • •	27
 Full-year earnings forecasts 	• • • • • • •	28
 Full-year earnings forecasts (1H/2H) 	• • • • • • •	29
 Full-year earnings forecasts by company 	• • • • • • •	30
 Planned store openings and closures 	• • • • • • •	32

Copyright Welcia Holdings Co., Ltd. Financial Results for the Third Quarter of Fiscal Year Ending February 2023



1 Outline of Financial Results

- Made Pupule Himawari a subsidiary through the acquisition of shares, effective December 1, 2021.
- The Group adopted the Accounting Standard for Revenue Recognition from the beginning of fiscal year ending February 2023.
- Made Kokumin Co., Ltd. and French Co., Ltd. wholly owned subsidiaries through the acquisition of shares, effective June 1, 2022.
- Welcia Yakkyoku, a consolidated subsidiary and the surviving company, absorbed Kanamitsu Yakuhin, effective June 1, 2022. The results of Welcia Yakkyoku for the same period of the previous year are calculated together with those of Kanamitsu Yakuhin.

Overview of FY2023 3Q



1. Outline of Financial Results	Act	ual results	Projections	Difference
Net sales	845	,986 million yer	n 829,200 million yen	16,786 million yen
Ordinary income	36	,568 million yer	n 36,940 million yen	-371 million yen
Net income attributable to owners of	of parent 21	,136 million yer	n 22,570 million yen	-1,433 million yen
2. Indicators		Actual results	s Projections	Difference
Existing-stores sales growth rate	* Existing-stores sales growth	3.2%	3.5%	-0.3%
(Products)	rates are compared with those before the adoption of the	2.2%	2.3%	-0.1%
(Dispensing)	revenue recognition standard.	7.0%	8.3%	-1.3%
Store openings (in Japan)		111 stores	s 111 stores	0 stores
Store closures (in Japan)		29 stores	s 24 stores	5 stores
M&A		165 stores	s 0 stores	165 stores
Number of stores as of the end of t	he term (in Japan)	2,704 stores	s 2,544 stores	160 stores
Dispensing pharmacy sales (in Jap	an) 168	,019 million yer	n 163,150 million yen	4,869 million yen
Composition ratio of dispensing sa	les	19.9%	b 19.7%	0.2%
Number of stores with dispensing pharmacy (in Japan)	* Change from the previou term-end: 138 stores	s 1,977 stores	s 1,978 stores	-1 store
Ratio of stores with dispensing pharmacy (in Japan)		74.4%	79.3%	-4.9%
Renovation (full renovation)		50 stores	s 75 stores	-25 stores
Number of stores open 24 hours		281 stores	6 –	-
3. Others	Act	ual results		
Composition ratio of PB products	6.2%	(Breakdown: Hapyco	om 16.3%, Topvalu 24.8%, Welcia PB	56.0 % , others 2.9%)
Number of stores with Welcafe		428 stores	6 –	_

*The ratio of stores with dispensing pharmacy is calculated excluding the number of cosmetics stores.

- Operating income and ordinary income fall short due to upfront costs associated with the acquisition of Kokumin and French as consolidated subsidiaries and the rise in utilities costs, despite the increase in OTC products sales due to the increase in the number of COVID-19 cases.
- Provision for loss on guarantees of Employee Stock Ownership ESOP Trust 1,120 million yen recorded as extraordinary loss.

Projections (Ratios of net sales indicated in Actual results Achievement rate parentheses (%)) Difference (%) 845,986 829,200 16.786 102.0 Net sales (100.0)(100.0)255,251 249,460 5,791 102.3 Gross operating profit (30.1)(30.2)223,783 216,470 7,313 103.4 SG&A expenses (26.5)(26.1)31,468 32,990 -1.521 95.4 **Operating income** (3.7)(4.0)36,568 36,940 -371 99.0 **Ordinary income** (4.3)(4.5)21,136 22,570 -1,433 Net income attributable 93.6 (2.5)(2.7)to owners of parent



- Double-digit revenue growth due to the consolidation of Pupule Himawari, Kokumin, and French and the growth of OTC products due to the increase in the number of COVID-19 cases.
- Profit increased due to higher sales and control of SG&A expenses, offset by higher utilities costs.

(Ratios of net sales		Actual results for th of the previc	•	Ref. Estimated former s		Difference related t	ce
indicated in parentheses (%))	Actual results		Y/Y (%)		Y/Y (%)	revenue recognitio	
Net sales	845,986 (100.0)	756,403 (100.0)	111.8	862,570 (100.0)	114.0 (100.0)	-16	6,583
Gross operating profit	255,251 (30.2)	233,620 (30.9)	109.3	267,936 (31.1)	114.7 (30.9)	-12	2,685
SG&A expenses	223,783 (26.5)	203,804 (27.0)	109.8	236,475 (27.5)	116.0 (27.0)	-12	2,692
Operating income	31,468 (3.7)	29,815 (3.9)	105.5	31,461 (3.6)	105.5 (3.9)		6
Ordinary income	36,568 (4.3)	32,943 (4.4)	111.0	36,561 (4.2)	111.0 (4.4)		6
Net income attributable to owners of parent	21,136 (2.5)	20,208 (2.7)	104.6	21,129 (2.5)	104.6 (2.7)		6

Results for FY2023 3Q (quarterly YoY change) (1)



		10)			20	, , , , , , , , , , , , , , , , , , ,	it. million yen)
(Ratios of net sales indicated in			Ref. Estimat the forme				Ref. Estimated	
parentheses) (%)		Y/Y (%)		Y/Y (%)		Y/Y (%)		Y/Y (%)
Net sales	267,716 (100.0)	107.6 (100.0)	273,177 (100.0)	109.8 (100.0)	295,035 (100.0)	113.7 (100.0)	300,787 (100.0)	115.9 (100.0)
Gross operating profit	78,431 (29.3)	105.1 (30.0)	82,622 (30.2)	110.7 (30.0)	92,193 (31.2)	110.8 (32.1)	96,580 (32.1)	116.1 (32.1)
SG&A expenses	70,717 (26.4)	105.0 (27.1)	74,936 (27.4)	111.3 (27.1)	75,918 (25.7)	112.1 (26.1)	80,284 (26.7)	118.5 (26.1)
Operating income	7,713 (2.9)	105.9 (2.9)	7,685 (2.8)	105.5 (2.9)	16,274 (5.5)	105.3 (6.0)	16,295 (5.4)	105.4 (6.0)
Ordinary income	10,495 (3.9)	118.6 (3.6)	10,467 (3.8)	118.3 (3.6)	17,478 (5.9)	107.3 (6.3)	17,499 (5.8)	107.4 (6.3)
Net income attributable to owners of parent	6,321 (2.4)	119.1 (2.1)	6,293 (2.3)	118.6 (2.1)	10,766 (3.6)	105.4 (3.9)	10,787 (3.6)	105.6 (3.9)
Remarks	April: Pollen peak r Revisions to May: Increased ou	ng of semi-emerger d antigen testing nonth shifted to Apr medical service fee tings during the nat	il s and NHI drug pric	,	Later half c July: Seventh wa August: Negotiatior Unrestricte	umin and French sul of the month: Record ave of COVID-19 ns concluded after th d summer vacation		vision
i terrai ko	May: Emergency o the infection		COVID-19 measure COVID-19 measure	s s, the 4th wave of	until the en July: Strong sale season / O August: Olympic ar NHI drug p	d of September es of seasonable pro lympic Games	y COVID-19 measure oducts after the end c es / Negotiations cond orable weather ections	of the rainy

Results for FY2023 3Q (quarterly YoY change) (2)



		30)				4Q	
(Ratios of net sales indicated in			Ref. Estimate the former					ed based on r standard
parentheses) (%)		Y/Y (%)		Y/Y (%)		Y/Y (%)		Y/Y (%)
Net sales	283,234 (100.0)	114.2 (100.0)	288,605 (100.0)	116.3 (100.0)				
Gross operating profit	84,626 (29.9)	111.6 (30.6)	88,734 (30.7)	117.1 (30.6)				
SG&A expenses	77,146 (27.3)	112.3 (27.7)	81,253 (28.1)	118.2 (27.7)				
Operating income	7,479 (2.6)	105.6 (2.9)	7,480 (2.6)	105.7 (2.9)				
Ordinary income	8,593 (3.0)	110.2 (3.1)	8,594 (3.0)	110.2 (3.1)				
Net income attributable to owners of parent	4,048 (1.4)	86.5 (1.9)	4,049 (1.4)	86.5 (1.9)				
	Increase in FY2022	le travel support sta in the prices of the 2 /en level temporaril	d arted highest number of p y as the yen's depre					
Remarks	measures Increase November: 70% of po	lifting of emergenc in tobacco tax	y or semi-emergenc	y COVID-19	2021–2022 December: January: February:	2 Made Pupule Himawari Vaccine testing package testing project at the tim and antigen testing) The 6th wave of COVID Semi-emergency COVID testing Semi-emergency COVID	e fixing promotion pro e of the spread of info -19 infections D-19 measures, free F	ection (free PCR PCR and antigen

Breakdown of financial results by company for FY2023 3Q (1)

- Welcia Yakkyoku: Increased revenue and profit due to higher sales of OTC products as a result of increased demand for antigen test kits and control of SG&A expenses.
- Kokumin:SG&A expenses increased mainly due to expenses related to POS system integration, etc., on the other hand, gross profit showed an improvement trend.
- Pupule Himawari: The gross profit margin improved and operating profit remained in the black mainly due to the review of its product policy and other factors.
 (Unit: million yen)

	W	elcia HD (d	consolidated)		Welcia Y	⁄akkyoku		Kok	umin	Pupule I	Himawari
(Ratios of net sales indicated in parentheses (%))			Ref. Est based on t stand	he former			Ref. Est based on t stan	he former		Ref. Estimated based on		Ref. Estimated based on
		Y/Y (%)		Y/Y (%)		Y/Y (%)		Y/Y (%)		the former standard		the forme standard
Net sales	845,986 (100.0)	111.8 (100.0)	862,570 (100.0)	114.0 (100.0)	720,378 (100.0)	104.1 (100.0)	734,215 (100.0)	106.1 (100.0)	20,374 (100.0)		37,005 (100.0)	
Gross operating profit	255,251 (30.2)	109.3 (30.9)	267,936 (31.1)	114.7 (30.9)	220,272 (30.6)	102.6 (31.0)	230,761 (31.4)	107.4 (31.0)	6,428 (31.6)		8,820 (23.8)	
SG&A expenses	223,783 (26.5)	109.8 (27.0)	236,475 (27.5)	116.0 (27.0)	188,369 (26.2)	101.7 (26.7)	198,858 (27.1)	107.4 (26.7)	6,770 (33.3)		8,790 (23.7)	
Operating income	31,468 (3.7)	105.5 (3.9)	31,461 (3.6)	105.5 (3.9)	31,903 (4.4)	108.0 (4.3)	31,903 (4.3)	108.0 (4.3)	-342 (_)		29 (0.1)	
Ordinary income	36,568 (4.3)	111.0 (4.4)	36,561 (4.2)	111.0 (4.4)	36,260 (5.0)	111.3 (4.7)	36,260 (4.9)	111.3 (4.7)	-219 (_)		609 (1.6)	1
Net income attributable to owners of parent	21,136 (2.5)	104.6 (2.7)	21,129 (2.5)	104.6 (2.7)	22,975 (3.2)	112.2 (3.0)	22,975 (3.1)	112.2 (3.0)	-265 (_)	-263 (_)	446 (1.2)	

Copyright Welcia Holdings Co., Ltd. Financial Results for the Third Quarter of Fiscal Year Ending February 2023

welc

(Unit: million yen)

welcia

	Mar	udai Saku	rai Pharm	acy		Shimizu	Yakuhin			Marue	Drug			vill and ers
(Ratios of net sales indicated in parentheses)			Ref. Est based former s	on the			Ref. Est based former s	on the			Ref. Est based former s	on the		Ref. Estimate d based on the
		Y/Y (%)		Y/Y (%)		Y/Y (%)		Y/Y (%)		Y/Y (%)		Y/Y (%)		former standard
Net sales	22,836 (100.0)	105.4 (100.0)	23,568 (100.0)	108.8 (100.0)	18,118 (100.0)	106.4 (100.0)	18,447 (100.0)	108.4 (100.0)	10,244 (100.0)	101.7 (100.0)	10,432 (100.0)	103.6 (100.0)	_ 17,028	_ 17,656
Gross operating profit	6,126 (26.8)	102.4 (27.6)	6,633 (28.1)	110.8 (27.6)	5,444 (30.1)	104.3 (30.6)	5,688 (30.8)	109.0 (30.6)	3,199 (31.2)	101.2 (31.4)	3,349 (32.1)	105.9 (31.4)	_ 4,960	_ 5,428
SG&A expenses	5,193 (22.7)	101.4 (23.6)	5,701 (24.1)	111.3 (23.6)	4,668 (25.8)	103.9 (26.4)	4,912 (26.6)	109.3 (26.4)	2,983 (29.1)	101.6 (29.2)	3,133 (30.0)	106.8 (29.2)	2,077 4,930	2,077 5,389
Operating income	932 (4.1)	108.3 (4.0)	932 (4.0)	108.3 (4.0)	776 (4.3)	107.4 (4.2)	776 (4.2)	107.4 (4.2)	215 (2.1)	95.5 (2.2)	215 (2.1)	95.5 (2.2)	-2,077 30	-2,077 39
Ordinary income	1,012 (4.4)	106.9 (4.4)	1,012 (4.3)	106.9 (4.4)	896 (4.9)	113.1 (4.7)	896 (4.9)	113.1 (4.7)	271 (2.7)	99.9 (2.7)	271 (2.6)	99.9 (2.7)	-2,077 -186	-2,077 -176
Net income attributable to owners of parent	645 (2.8)	104.8 (2.8)	645 (2.7)	104.8 (2.8)	605 (3.3)	117.2 (3.0)	605 (3.3)	117.2 (3.0)	174 (1.7)	82.2 (2.1)	174 (1.7)	82.2 (2.1)	-2,077 -1,367	-2,077 -1,357

Copyright Welcia Holdings Co., Ltd. Financial Results for the Third Quarter of Fiscal Year Ending February 2023



- Products: Sales increased mainly owing to the increased demand for OTC products despite the consumer awareness of the need to protect their livelihoods increased due to price hikes.
- Dispensing: The number of prescriptions increased mainly owing to the increased number of stores with dispensing pharmacy, despite the revisions to dispensing fees and NHI drug prices.

		2021						20	22					
		December	January	February	March	April	May	June	July	August	September	October	November	December
	Welcia Yakkyoku	1.4	7.4	3.0	2.7	1.6	0.0	1.4	4.7	4.3	4.1	4.6	3.9	11.0
es	Shimizu Yakuhin	2.2	8.4	9.4	1.7	5.2	1.0	3.6	4.8	5.6	6.3	8.6	4.8	13.4
g Stores	Marudai Sakurai Pharmacy	-0.8	5.5	9.0	5.3	3.3	1.8	1.4	7.7	6.7	4.8	4.9	10.3	9.6
Existing 3	MASAYA	7.9	8.3	-8.6	14.5	11.5	3.8	15.4	7.4	10.2	8.8	-9.6	16.8	1.6
Ш	Kanamitsu Yakuhin	6.0	24.1	-0.6	2.8	5.6	-4.2							
	YODOYA	-2.7	6.0	1.1	5.6	5.5	1.6	4.1	6.6	9.9	5.6	4.7	9.1	10.7
	Marue Drug	-0.5	11.8	8.4	2.8	0.7	-0.2	0.0	1.2	2.0	2.4	0.5	0.3	6.9
	Pupule Himawari													1.6
	Group total Net sales	1.3	7.5	3.4	2.9	1.8	0.1	1.6	4.8	4.5	4.1	4.6	4.2	10.4
	(Products)	-1.2	6.5	2.3	0.6	1.0	-1.6	0.4	4.8	3.5	3.1	4.2	3.6	11.5
	(Dispensing)	11.8	11.5	6.4	9.0	4.9	8.3	6.3	4.8	8.5	8.3	6.3	6.3	5.9
	No. of customers	-1.0	3.9	0.5	-0.3	-0.6	-0.7	0.4	2.4	1.8	2.4	1.7	1.8	6.3
	Sales per customer	2.3	3.6	2.9	3.2	2.4	0.8	1.2	2.4	2.7	1.7	2.9	2.4	4.1
S	Group total Net sales	10.0	16.6	11.5	10.4	10.3	8.5	13.5	17.1	16.4	16.0	16.4	15.7	18.0
All stores	No. of customers	8.9	14.5	10.1	9.0	9.1	8.9	14.5	16.8	15.8	16.1	15.4	15.2	15.2
All	Sales per customer	1.1	2.1	1.4	1.4	1.2	-0.4	-1.0	0.3	0.6	-0.1	1.0	0.5	2.8

* Kokumin and French have been included in the calculation of monthly sales growth rate of all stores since June 2022. However, since the stores of the companies are regarded as new stores, they are not included in the calculation of monthly sales growth rate of existing stores.

* Pupule Himawari became an existing store in December 2022.

(Unit: %)

- OTC products: Demand for antigen test kits, combination cold remedies, antipyretic analgesics, and other products expanded.
- Cosmetics: Improving trend of makeup-related products due to increased opportunities for going out.
- Dispensing: Sales of dispensing drugs increased owing to the increased number of prescriptions due to the increase number of stores with dispensing pharmacy, despite the revisions to dispensing fees and NHI drug prices. (Unit: million yen)

		V	Velcia HD.(d	consolidated			Welcia Y	′akkyoku		Kok	umin	Pupule H	limawari
	os of net sales n parentheses (%))		Y/Y (%)	Ref. Estima on the	,		Y/Y (%)	Ref. Estim on the	ated based former dard Y/Y (%)		Ref. Estimated based on the former standard		Ref. Estimated based or the forme standard
	OTC products	171,344 (20.3)	114.2 (19.8)	175,335 (20.3)	116.9 (19.8)	145,086 (20.1)	106.0 (19.8)	148,592 (20.2)	108.6 (19.8)	5,253 (25.8)	5,264 (25.7)	7,160 (19.3)	7,32 (19.4
	Cosmetics	132,276 (15.6)	112.0 (15.6)	135,412 (15.7)	114.7 (15.6)	105,426 (14.6)	101.7 (15.0)	107,804 (14.7)	104.0 (15.0)	5,324 (26.1)	5,359 (26.2)	6,554 (17.7)	6,71 (17.8
	Household goods	116,908 (13.8)	106.7 (14.5)	120,624 (14.0)	110.1 (14.5)	99,800 (13.9)	99.9 (14.4)	102,920 (14.0)	103.1 (14.4)	1,399 (6.9)	1,438 (7.0)	5,943 (16.1)	6,083 (16.1
	Food products	187,918 (22.2)	110.2 (22.6)	192,863 (22.4)	113.1 (22.6)	161,263 (22.4)	102.9 (22.7)	165,402 (22.5)	105.5 (22.7)	722 (3.5)	725 (3.5)	11,372 (30.7)	11,61 (30.8
	Others	68,617 (8.1)	113.0 (8.0)	70,079 (8.1)	115.4 (8.0)	55,752 (7.8)	103.8 (7.7)	56,945 (7.8)	106.0 (7.7)	396 (2.0)	414 (2.1)	4,318 (11.7)	4,46 (11.7
۲ I	Total sales of products	677,063 (80.0)	111.2 (80.5)	694,314 (80.5)	114.0 (80.5)	567,330 (78.8)	103.0 (79.6)	581,666 (79.2)	105.6 (79.6)	13,097 (64.3)	13,202 (64.5)	35,349 (95.5)	36,20 (95.8
	Dispensing	168,019 (19.9)	114.0 (19.5)	168,255 (19.5)	114.1 (19.5)	152,325 (21.1)	107.7 (20.4)	152,549 (20.8)	107.8 (20.4)	7,266 (35.7)	7,269 (35.5)	1,571 (4.2)	1,57 (4.2
	Subtotal	845,082 (99.9)	111.7 (100.0)			719,655 (99.9)	104.0 (100.0)			20,364 (100.0)		36,920 (99.7)	
C	ommission income	904 (0.1)	_ (_)			722 (0.1)	_ (_)			10 (0.0)		85 (0.3)	
	Total	845,986 (100.0)	111.8 (100.0)	862,570 (100.0)	114.0 (100.0)	720,378 (100.0)	104.1 (100.0)	734,215 (100.0)	106.1 (100.0)	20,374 (100.0)	20,471 (100.0)	37,005 (100.0)	37,77 (100.0

	M	arudai Saku	ırai Pharmad	cy 🛛		Shimizu	Yakuhin			Marue	```	innorr yorr)
Ratios of net sales ted in parentheses (%))			Ref. Estima on the stan	former dard	F				-		Ref. Estima on the stan	former dard
		Y/Y (%)		Y/Y (%)		Y/Y (%)		Y/Y (%)		Y/Y (%)		Y/Y (%)
OTC products	5,060 (22.2)	109.6 (21.3)	5,193 (22.0)	112.5 (21.3)	4,207 (23.2)	103.0 (24.0)	4,287 (23.2)	104.9 (24.0)	2,824 (27.6)	98.3 (28.5)	2,883 (27.6)	100.3 (28.5)
Cosmetics	3,519 (15.4)	101.9 (15.9)	3,623 (15.4)	104.9 (15.9)	3,139 (17.3)	103.8 (17.8)	3,199 (17.3)	105.8 (17.8)	1,962 (19.2)	96.4 (20.2)	2,005 (19.2)	98.6 (20.2)
Household goods	3,885 (17.0)	104.0 (17.2)	4,022 (17.1)	107.7 (17.2)	2,975 (16.4)	100.9 (17.3)	3,093 (16.8)	104.9 (17.3)	1,694 (16.5)	97.2 (17.3)	1,732 (16.6)	99.5 (17.3)
Food products	6,138 (26.9)	103.1 (27.5)	6,461 (27.4)	108.5 (27.5)	3,801 (21.0)	110.6 (20.2)	3,863 (20.9)	112.4 (20.2)	1,717 (16.8)	103.3 (16.5)	1,762 (16.9)	106.0 (16.5)
Others	2,462 (10.7)	104.7 (10.9)	2,520 (10.7)	107.2 (10.9)	1,180 (6.6)	105.4 (6.5)	1,203 (6.6)	107.5 (6.5)	380 (3.7)	115.4 (3.4)	389 (3.8)	118.2 (3.4)
Total sales of products	21,066 (92.2)	104.8 (92.8)	21,822 (92.6)	108.5 (92.8)	15,304 (84.5)	104.7 (85.8)	15,648 (84.8)	107.1 (85.8)	8,579 (83.8)	99.2 (85.9)	8,773 (84.1)	101.5 (85.9)
Dispensing	1,743 (7.6)	112.5 (7.2)	1,746 (7.4)	112.7 (7.2)	2,795 (15.4)	116.0 (14.2)	2,799 (15.2)	116.2 (14.2)	1,656 (16.2)	116.3 (14.1)	1,658 (15.9)	116.4 (14.1)
Subtotal	22,810 (99.8)	105.3 (100.0)			18,100 (99.9)	106.3 (100.0)			10,236 (100.0)	101.7 (100.0)		
Commission income	26 (0.2)	_ (_)			18 (0.1)	_ (_)			8 (0.0)	_ (_)		
Total	22,836 (100.0)	105.4 (100.0)	23,568 (100.0)	108.8 (100.0)	18,118 (100.0)	106.4 (100.0)	18,447 (100.0)	108.4 (100.0)	10,244 (100.0)	101.7 (100.0)	10,432 (100.0)	103.6 (100.0)



- OTC products: Increased due to expanded demand for antigen test kits, combination cold remedies, antipyretic analgesics, and other products.
- Food products: Declined mainly owing to the strategic sales promotions as a countermeasure against customers' conservative buying of food due to price increases.
- Dispensing: Decreased from the previous year due to the effect of the revisions to dispensing fees and NHI drug prices.

(Unit: %)

		W	/elcia HD (consolidate	ed)		Welcia Y	′akkyoku		Kok	umin	Pupule H	limawari
				Ref. Es based on f stan				Ref. Es based on stan			Ref. Estimate d based		Ref. Estimate d based
			Y/Y change		Y/Y change		Y/Y change		Y/Y change		on the former standard		on the former standard
	OTC products	40.1	-0.3	40.9	0.5	40.3	-0.2	41.0	0.5	36.9	37.0	40.4	41.7
	Cosmetics	32.7	-1.5	34.3	0.1	32.8	-1.3	34.3	0.2	29.8	30.3	31.2	32.8
	Household goods	27.7	-0.7	28.9	0.5	28.1	-0.5	29.3	0.7	28.9	28.6	21.8	23.6
	Food products	18.3	-1.8	19.5	-0.6	18.8	-1.5	20.0	-0.3	23.5	23.6	11.5	13.4
	Others	16.3	1.2	18.1	3.0	16.1	1.1	17.9	2.9	30.1	30.4	15.2	17.9
	otal sales of products	28.0	-0.8	29.3	0.5	28.3	-0.6	29.5	0.6	32.2	32.4	23.2	25.0
D	Dispensing	38.4	-0.9	38.4	-0.9	38.8	-0.6	38.9	-0.5	30.3	30.3	34.4	34.4
Sı	ubtotal	30.1	-0.8			30.5	-0.5			31.5		23.7	
-	nmission ncome	100.0	_			100.0	_			100.0		100.0	
	Total	30.2	-0.7	31.1	0.2	30.6	-0.4	31.4	0.4	31.6	31.7	23.8	25.4



(Unit: %)

		Ma	arudai Sakı	urai Pharm	acy		Shimizu	Yakuhin			Marue	e Drug	
				Ref. Estima on the stan	former dard			Ref. Es based on f stan	the former dard			Ref. Est based on t stan	the former dard
			Y/Y change		Y/Y change		Y/Y change		Y/Y change		Y/Y change		Y/Y change
	OTC products	40.4	-0.7	41.7	0.6	39.9	-0.5	40.6	0.2	38.5	0.1	39.3	0.9
	Cosmetics	31.3	-1.5	33.2	0.4	32.6	-1.3	33.8	-0.1	33.0	-0.8	34.5	0.7
	Household goods	24.7	-1.3	26.5	0.5	28.8	1.2	29.5	1.9	26.7	-0.2	28.0	1.1
	Food products	16.2	-1.3	17.6	0.1	18.1	-1.5	19.3	-0.3	17.5	-1.1	18.6	0.0
	Others	12.5	-1.2	14.5	0.8	14.1	0.4	15.8	2.1	18.0	1.6	20.1	3.7
	Total sales of products	25.7	-1.0	27.2	0.5	28.8	-0.7	29.8	0.3	29.8	-0.6	30.9	0.5
	Dispensing	39.7	-0.4	39.8	-0.3	36.3	-1.3	36.4	-1.2	38.2	0.4	38.3	0.5
	Subtotal	26.7	-0.9			30.0	-0.6			31.2	-0.2		
(Commission income	100.0	_			100.0	_			100.0	_		
	Total	26.8	-0.8	28.1	0.5	30.1	-0.5	30.8	0.2	31.2	-0.2	32.1	0.7




- Increase due to the consolidation of Pupule Himawari, Kokumin, and French
- Labor costs continue to benefit from man-hour control measures
- In others, the utilities costs have risen significantly due to higher unit prices.

(Unit: million	yen)
----------------	------

	W	/elcia HD (consolidate	d)		Welcia Y	akkyoku		Koki	umin	Pupule Himawari	
(Ratios of net sales indicated in parentheses (%))			Ref. Estima on the stan	former			Ref. Estima on the stand	former		Ref. Estimated based on		Ref. Estimated based on
		Y/Y (%)		Y/Y (%)		Y/Y (%)		Y/Y (%)		the former standard		the former standard
Labor costs	116,615 (13.8)	111.9 (13.8)		111.9 (13.8)	99,367 (13.8)	104.6 (13.7)	99,367 (13.5)	104.6 (13.7)	3,016 (14.8)	3,016 (14.7)	4,286 (11.6)	4,286 (11.3)
Advertising expenses	3,633 (0.4)	24.3 (2.0)	1 1	109.4 (2.0)	2,564 (0.4)	20.0 (1.9)	13,054 (1.8)	101.7 (1.9)	121 (0.6)	173 (0.8)	188 (0.5)	978 (2.6)
Rent	38,665 (4.6)	120.2 (4.3)		120.2 (4.3)	32,112 (4.5)	108.5 (4.3)	32,112 (4.4)	108.5 (4.3)	2,121 (10.4)	2,121 (10.4)	1,695 (4.6)	1,695 (4.5)
Others	64,868 (7.7)	123.6 (6.9)		123.6 (6.9)	54,324 (7.5)	113.8 (6.8)	54,324 (7.4)	113.8 (6.8)	1,510 (7.5)	1,510 (7.5)	2,620 (7.0)	2,620 (7.0)
Total	223,783 (26.5)	109.8 (27.0)	1 1	116.0 (27.0)	188,369 (26.2)	101.7 (26.7)	198,858 (27.1)	107.4 (26.7)	6,770 (33.3)	6,822 (33.4)	8,790 (23.7)	9,580 (25.4)

	Ma	arudai Saku	ırai Pharma	су		Shimizu	Yakuhin		Marue Drug			
(Ratios of net sales indicated in			Ref. Estima				Ref. Estima				Ref. Estima	
parentheses (%))		Y/Y (%)										
Labor costs	2,800 (12.3)	111.6 (11.6)	2,800 (11.9)	111.6 (11.6)	2,547 (14.1)	105.7 (14.2)	2,547 (13.8)	105.7 (14.2)	1,722 (16.8)	104.1 (16.4)	1,722 (16.5)	104.1 (16.4)
Advertising expenses	163 (0.7)	26.2 (2.9)	670 (2.8)	107.4 (2.9)	66 (0.4)	21.4 (1.8)		100.4 (1.8)	87 (0.9)	35.3 (2.5)	237 (2.3)	96.2 (2.5)
Rent	619 (2.7)	104.8 (2.7)	619 (2.6)	104.8 (2.7)	870 (4.8)	106.6 (4.8)	1	106.6 (4.8)	434 (4.2)	101.6 (4.2)	434 (4.2)	101.6 (4.2)
Others	1,609 (7.0)	115.2 (6.4)	1,609 (6.8)	115.2 (6.4)	1,183 (6.5)	123.5 (5.6)	1 1	123.5 (5.6)	738 (7.2)	121.9 (6.1)	738 (7.0)	121.9 (6.1)
Total	5,193 (22.7)	101.4 (23.6)	5,701 (24.1)	111.3 (23.6)	4,668 (25.8)	103.9 (26.4)		109.3 (26.4)	2,983 (29.1)	101.6 (29.2)	3,133 (30.0)	106.8 (29.2)



- Decrease in gross profit margin due to revisions to dispensing fees in April 2022
- The ratio of stores with dispensing pharmacy decreased due to the consolidation of Pupule Himawari and Kokumin (increased in existing stores)

	FY202	20 3Q	FY202	21 3Q	FY202	22 3Q	FY2023 3Q	
		Y/Y Y/Y change		Y/Y Y/Y change		Y/Y Y/Y change		Y/Y Y/Y change
Dispensing pharmacy sales (Million yen)	114,036	119.7%	128,054	112.3%	147,415	115.1%	168,019	114.0%
No. of prescriptions (in the thousands)	11,638	117.2%	11,858	101.9%	14,137	119.2%	16,039	113.5%
Prescription unit price (yen)	9,798	102.1%	10,799	110.2%	10,428	96.6%	10,475	100.5%
Gross profit margin (%)	37.5	-0.3	38.3	0.8	39.3	1.0	38.4	-0.9
No. of stores with								
dispensing pharmacy (stores)	1,388	147	1,590	202	1,792	202	1,977	185
Ratio of stores with dispensing pharmacy (%)	71.1	1.9	74.0	2.9	79.4	5.4	74.4	-5.0

*The ratio of stores with dispensing pharmacy is calculated excluding the number of cosmetics stores.

*The Group adopted the Accounting Standard for Revenue Recognition from the beginning of fiscal year ending February 2023.



The number of stores with dispensing pharmacy increased by 185 over one year from the end of the same period of the previous year.

		ia HD lidated)	Welcia Y	′akkyoku	Kokumin	Pupule Himawari		Sakurai macy	Shimizu	Yakuhin	Marue	e Drug
	FY2022 3Q	FY2023 3Q	FY2022 3Q	FY2023 3Q	FY2023 3Q	FY2023 3Q	FY2022 3Q	FY2023 3Q	FY2022 3Q	FY2023 3Q	FY2022 3Q	FY2023 3Q
Dispensing pharmacy sales (Million yen)	147,415	168,019	141,488	152,325	7,266	1,571	1,549	1,743	2,409	2,795	1,424	1,656
No. of prescriptions (in the thousands)	14,137	16,039	13,542	14,804	407	131	174	204	227	271	121	142
Prescription unit price (yen)	10,428	10,475	10,447	10,289	17,837	11,922	8,880	8,543	10,611	10,297	11,690	11,659
No. of stores with dispensing pharmacy (stores)	1,792	1,977	1,692	1,792	46	20	33	42	38	42	21	25
Ratio of stores with dispensing pharmacy (%)	79.4	74.4	83.6	84.6	29.5	14.9	36.7	44.2	60.3	63.6	36.8	42.4
No. of stores as of end of the fiscal year (stores)	2,258	2,656	2,024	2,118	156	134	90	95	63	66	57	59

*The ratio of stores with dispensing pharmacy is calculated excluding the number of cosmetics stores.

*The Group adopted the Accounting Standard for Revenue Recognition from the beginning of fiscal year ending February 2023.



Increase due to the acquisition of Kokumin and French as consolidated subsidiaries
 889 new graduates (420 pharmacists and 469 career-track employees employed in April 2022)

	,	consolidated) Change from the previous term-end	Welcia Yakkyoku	Kokumin	Pupule Himawari	Marudai Sakurai Pharmacy	Shimizu Yakuhin	Marue Drug
No. of employees (Person)	14,813	1,519	11,562	739	659	457	349	351
No. of temporary employees (based on 8h/employee)	25,611	1,131	22,253	559	1,009	709	548	93

No. of pharmacists (enrollment)	7,656	857	6,880	393	59	87	123	93
No. of registered sales clerks (enrollment)	17,581	914	14,272	697	974	631	485	332
No. of pharmacists per store (persons in Japan)	2.88	0.06	3.25	2.52	0.44	0.92	1.86	1.58
No. of registered sales clerks per store (persons in Japan)	6.62	-0.29	6.74	4.47	7.27	6.64	7.35	5.63

*The numbers of pharmacists and registered sales clerks, registered sales clerks per store are calculated by excluding cosmetics stores.



• Number of stores opened (in Japan): 111 (vs. planned: 0 stores)

• Number of operating months (in Japan) Actual 591 months (vs planned: 27 months)

(Unit: No. of stores)

				Increase/ decrease	Increase/	Оре	nings	Clos	ures	End of
			End of Feb. 2022	resulting from subsidiaries or business transfer	decrease resulting from M&A	FIOJECTIONS	Actual results	Projections	Actual results	November 2022
		Welcia Yakkyoku (NARCIS)	2,023 (8)	—	26	90 (1)	94 (1)	21 (—)	16 (—)	2,127 (9)
		Marudai Sakurai Pharmacy	92		—	6	3	1		95
	~	Shimizu Yakuhin	65	—	—	4	3	1	2	66
	company	Marue Drug	58	—	—	3	2	1	1	59
	mo	YODOYA	25	—	—	—	—	—	—	25
	By c	Kanamitsu Yakuhin	26	—	-26	—	—	—	—	—
	ш	MASAYA	36	—	—	4	3	—	—	39
		Pupule Himawari	132	—	—	4	3	—	1	134
		Kokumin	—	162	—	—	3	—	9	156
		French	_	3	—	—	—	—	—	3
		Hokkaido	—	7	—	—	—	—	—	7
		Tohoku	184	1	-	8	6	2	1	190
	~	Kanto	1,115	54	—	26	29	8	8	1,190
	area	Chubu	527	1	—	25	19	7	3	544
	By a	Kinki	399	86	—	31	36	6	15	506
	_	Chugoku	161	2	—	15	11	1	2	172
		Shikoku	68	—	—	3	5	—	—	73
		Kyushu	3	14	—	3	5	—	—	22
		In Japan	2,457	165	—	111	111	24	29	2,704
		Overseas	11	_	—	1	1	_	—	12
		Consolidated	2,468	165	—	112	112	24	29	2,716



(1) Pursuing expertise and strengthening marketing capabilities

- Promoting the establishment of stores with dispensing pharmacy—The number of stores with dispensing pharmacy increased by 138 stores from the previous term-end, and the number of stores opened on Saturdays increased by 124 stores over the same period
 Operating the online qualification verification system in 1,740 stores and drug pick up lockers in 192 stores
- 2) Active participation in the free PCR test business, etc. and continued sales of antigen test kits
- 3) Development and expanded sales of PB products at Karada Welcia and Kurashi Welcia: Total 120 SKUs as of the end of November 2022
- 4) Strengthening the format: Continuing experiments in the "food" category in Hokuriku, Kyushu, and Makuhari

(2) Thorough efforts to improve store operational efficiency and improvement of profitability

- 1) Deep cultivation of man-hour control through utilization of work management systems and visualization of shifts
- 2) Strengthening counseling for OTC products and cosmetics using digital tools

(3) Promoting sustainability management

- 1) Reduction of environmental impact through the Bottle-to-Bottle recycling of PET bottles and conversion of cutlery materials
- 2) Implementation of the Eco-activities Points program, in which points are earned by shopping of products targeted for energy conservation and CO2 reduction



i-Chart

Support tools such as full service and product suggestions at the beauty counter, also available for the ledger function

- This will lead to the counseling and continuous visits through skin diagnosis, etc.
- Promote sales for members and encourage repeat purchases.



* Introduced at Welcia Yakkyoku and Shimizu Yakuhin, and Yodoya.

Meds Navigation A web tool to support registered sales clerks for customer service and product selection

- Developed at Welcia Yakkyoku in the second half as a customer support tool for OTC products.
- This will lead to the strengthening of health care counseling.





We made Fukuyakuhin Co., Ltd. a subsidiary through the acquisition of shares, effective December 1, 2022.





Future integration process

- 1. Basic and POS systems have been installed
- 2. Changes have been made to the distribution system
- 3. Aggressive promotion of opening of stores with dispensing pharmacy
- 4. Introduction of PB products

25 stores in Okinawa Prefecture (including 9 stores with dispensing pharmacy)



2 Earnings Forecast for FY2023

- Made Pupule Himawari into a subsidiary through the acquisition of shares, effective December 1, 2021.
- The Group adopted the Accounting Standard for Revenue Recognition from the beginning of fiscal year ending February 2023.
- Welcia Yakkyoku, a consolidated subsidiary and the surviving company, absorbed Kanamitsu Yakuhin, effective June 1, 2022. The plan and results of the previous fiscal year of Kanamitsu Yakuhin after June 1, 2022 are included in that of Welcia Yakkyoku described in this section.



1. Projections

- Net sales
- Ordinary income
- Net income attributable to owners of parent
- 2. Indicators
- Existing-stores sales growth rate

(Goods)

(Dispensing)

- Openings
- Closures
- No. of stores as of end of the fiscal year
- Dispensing pharmacy sales (in Japan)
 Number of stores with dispensing pharmacy
- (in Japan)
- 3. Priority measures
- Opening new pharmacies
- Renovation (full renovation)

- 1,110 billion yen (Y/Y change: 108.2%)
 51.6 billion yen (Y/Y change: 108.4%)
 28.4 billion yen (Y/Y change: 107.4%)
 3.4%

 *Existing-stores sales growth rates are compared with those before the adoption of the revenue recognition standard.
 129 stores (in Japan: 128; overseas: 1)
 25 stores (in Japan: 25; overseas: 0)
 - 2,572 stores (in Japan: 2,560; overseas: 12)
- 220.8 billion yen (Y/Y change: 110.8%)
 - 1,975 stores (Ratio of stores with dispensing 78.7%)
 - 152 stores (in Japan: 152; overseas: 0)

85 stores

* The ratio of stores with dispensing pharmacy is calculated excluding the number of cosmetics stores from the number of stores at the end of the term.

Copyright Welcia Holdings Co., Ltd. Financial Results for the Third Quarter of Fiscal Year Ending February 2023



(1) Pursuing expertise and strengthening marketing capabilities

- 1) Strengthening regional responses through the area office system and area operations (marketing, dispensing and cosmetics)
- 2) Promoting stores with dispensing pharmacy
- 3) Developing and expanding sales of PB products
- 4) Format enhancements
- (2) Thorough efforts to improve store operational efficiency and improvement of profitability
 - 1) Optimization of man-hours (pursuing man-hour sales)
 - 2) Strengthening regional cooperation and interpersonal operations (mechanization, utilization of dispensing operations, and enhancement of specialized education)
 - 3) Promotion of DX

(3) Promoting sustainability management

1) Promoting "the corporate philosophy and the realization of a sustainable society" through our core business

Full-year earnings forecasts



	Results fo 202		Fiscal 2	2023 Fore	cast	(Unit: million yen) [Reference] Estimated based on the former standard Fiscal 2023 Forecast			
	Amount	Composition ratio	Amount	Composition ratio	Y/Y	Amount	Composition ratio	Y/Y	
Net sales	1,025,947	100.0%	1,110,000	100.0%	108.2%	1,131,000	100.0%	110.2%	
(Ratio of stores with dispensing pharmacy)	199,208	19.4%	220,800	19.9%	110.8%	220,800	19.5%	110.8%	
Gross operating profit	320,944	31.3%	338,700	30.5%	105.5%	355,600	31.4%	110.8%	
SG&A expenses	277,925	27.1%	291,700	26.3%	105.0%	308,600	27.2%	111.0%	
Operating income	43,018	4.2%	47,000	4.2%	109.3%	47,000	4.2%	109.3%	
Ordinary income	47,590	4.6%	51,600	4.6%	108.4%	51,600	4.6%	108.4%	
Net income attributable to owners of parent	26,453	2.6%	28,400	2.6%	107.4%	28,400	2.5%	107.4%	
Existing-store sales growth rate								3.4%	

* Quarterly plans are stated in the "Supplementary material about the settlement of accounts" attached hereto.



	1⊦	l	[Reference] on the fo	Estimate ormer star 1H		2⊦	l	(Unit: million yen) [Reference] Estimated based on the former standard 2H		
	Amount	Composition ratio	Amount	Composition ratio	Y/Y	Amount	Composition ratio	Amount	Composition ratio	Y/Y
Net sales	555,800	100.0%	566,500	100.0%	111.5%	554,200	100.0%	564,500	100.0%	109.1%
(Ratio of stores with dispensing pharmacy)	107,850	19.4%	107,850	19.0%	110.4%	112,950	20.4%	112,950	20.0%	111.2%
Gross operating profit	168,240	30.3%	176,840	31.2%	112.1%	170,460	30.8%	178,760	31.7%	109.6%
SG&A expenses	142,880	25.7%	151,480	26.7%	112.1%	148,820	26.9%	157,120	27.9%	110.0%
Operating income	25,360	4.6%	25,360	4.5%	111.5%	21,640	3.9%	21,640	3.8%	106.7%
Ordinary income	28,540	5.1%	28,540	5.0%	113.5%	23,060	4.2%	23,060	4.1%	102.7%
Net income attributable to owners of parent	17,560	3.2%	17,560	3.1%	113.1%	10,840	2.0%	10,840	1.9%	99.2%
Existing-store sales growth rate					3.2%					3.7%

* Quarterly plans are stated in the "Supplementary material about the settlement of accounts" attached hereto.



	Welcia	a HD (consoli	dated)	W	′elcia Yakkyok	ĸu		Maruda	ai Sakurai Pha	armacy
(Ratios of net sales indicated in parentheses)		[Refer Estimated b former s	ased on the		[Reference] Estimated based on the former standard		Pupule Himawari		[Reference] Estimated based on the former standard	
	Amount	Amount	Y/Y	Amount	Amount	Y/Y	Amount	Amount	Amount	Y/Y
Net sales	1,110,000 (100.0%)	1,131,000 (100.0%)	110.2% (100.0%)	972,385 (100.0%)	988,526 (100.0%)	106.6% (100.0%)	48,931 (100.0%)	29,983 (100.0%)	30,769 (100.0%)	105.9% (100.0%)
Gross operating profit	338,700 (30.5%)	355,600 (31.4%)	110.8% (31.3%)	301,049 (31.0%)	315,134 (31.9%)	107.8% (31.5%)	12,123 (24.8%)	7,981 (26.6%)	8,660 (28.1%)	106.6% (28.0%)
SG&A expenses	291,700 (26.3%)	308,600 (27.2%)	111.0% (27.1%)	255,225 (26.3%)	269,310 (27.3%)	107.8% (26.9%)	11,620 (23.8%)	6,779 (22.6%)	7,458 (24.2%)	106.3% (24.2%)
Operating income	47,000 (4.2%)	47,000 (4.2%)	109.3% (4.2%)	45,824 (4.7%)	45,824 (4.6%)	107.4% (4.6%)	502 (1.0%)	1,202 (4.0%)	1,202 (3.9%)	108.0% (3.8%)
Ordinary income	51,600 (4.6%)	51,600 (4.6%)	108.4% (4.6%)	50,298 (5.2%)	50,298 (5.1%)	107.1% (5.1%)	515 (1.1%)	1,258 (4.2%)	1,258 (4.1%)	103.2% (4.2%)
Net income attributable to owners of parent	28,400 (2.6%)	28,400 (2.5%)	107.4% (2.6%)	28,720 (3.0%)	28,720 (2.9%)	106.6% (2.9%)	301 (0.6%)	792 (2.6%)	792 (2.6%)	101.6% (2.7%)



					(011	t. million yen)	
	SI	nimizu Yakuh	in		Marue Drug		
(Ratios of net sales indicated in parentheses)		[Refer Estimated b former s	ased on the		[Refer Estimated b former s	ased on the	Goodwill and others
	Amount	Amount	Y/Y	Amount	Amount	Y/Y	
Net sales	24,243 (100.0%)	24,600 (100.0%)	107.8% (100.0%)	14,017 (100.0%)	14,218 (100.0%)	104.1% (100.0%)	20,440
Gross operating profit	7,356 (30.3%)	7,702 (31.3%)	108.5% (31.1%)	4,337 (30.9%)	4,538 (31.9%)	103.8% (32.0%)	 5,853
SG&A expenses	6,331 (26.1%)	6,677 (27.1%)	108.2% (27.0%)	3,905 (27.8%)	4,106 (28.9%)	103.5% (29.0%)	1,903 5,936
Operating income	1,025 (4.2%)	1,025 (4.2%)	110.5% (4.1%)	431 (3.1%)	431 (3.0%)	106.3% (3.0%)	-1,903 -83
Ordinary income	1,153 (4.8%)	1,153 (4.7%)	111.8% (4.5%)	470 (3.4%)	470 (3.3%)	102.0% (3.4%)	-1,903 -192
Net income attributable to owners of parent	660 (2.7%)	660 (2.7%)	101.3% (2.9%)	300 (2.1%)	300 (2.1%)	44.6% (4.9%)	-1,903 -472



(Unit: No. of Stores)

			Actual number at the beginning of the term	Increase/decrease resulting from M&A	Openings	Closures	Estimated number at the end of the term
	By company	Welcia Yakkyoku	2,023	26	105	22	2,132
		(NARCIS)	(8)		(1)		(9)
		Marudai Sakurai Pharmacy	92	—	6	1	97
		Shimizu Yakuhin	65	—	6	1	70
		Marue Drug	58		3	1	60
		YODOYA	25	—	—	_	25
		Kanamitsu Yakuhin	26	-26	—	—	—
		MASAYA	36	—	4	—	40
		Pupule Himawari	132	—	4	_	136
	By area	Tohoku	184	_	10	2	192
		Kanto	1,115		31	8	1,138
		Chubu	527		31	7	551
		Kinki	399		34	7	426
		Chugoku	161	—	15	1	175
		Shikoku	68	—	4	—	72
		Kyushu	3	—	3		6
		In Japan	2,457		128	25	2,560
		Overseas	11	_	1		12
		Consolidated	2,468	—	129	25	2,572
(In Japan)		No. of stores with dispensing pharmacy	1,839		152	16	1,975
		Ratio of stores with dispensing pharmacy	76.2%				78.7%

* The ratio of stores with dispensing pharmacy is calculated excluding the number of cosmetics stores (MASAYA stores, and NARCIS stores operated by Welcia Yakkyoku)



This material is prepared to provide investors with information on the management and financial conditions of Welcia Holdings Co., Ltd. for the purpose of helping them deepen their understanding of the Company.

Please understand and acknowledge the following points before referring to this material:

- The results contained in this material have not been audited by an auditing firm.
- Earnings forecasts and other forward-looking statements found in this material are based on assumptions the Company made with every effort possible at the time of preparation.
- Please understand that actual results may differ from any forecasts and expectations contained in this material.
- All investment decisions should be made solely at the discretion of investors themselves.
- The greatest care is taken to ensure that all information contained in this material is accurate. However, please be aware that there may be discrepancies and errors due to unavoidable reasons.